Intercept reports patient death in Phase II NASH trial of Ocaliva

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) lost $17.90 (13%) to $117.13 on Monday after reporting a patient death in the long-term extension of the Phase II CONTROL trial of Ocaliva obeticholic acid to treat non-alcoholic steatohepatitis patients with fibrosis and compensated cirrhosis.

The patient died due to acute renal and liver failure, according to the company. The trial's principal investigator and an independent DSMC determined the death was "unlikely related" to Ocaliva. However, Intercept said it could not be ruled out...